BDNF and Cerebellar Ataxia.
Friedreich’s ataxia
cerebellar development
cerebellar mutants
neurotrophin
rotorod
spinocerebellar ataxia
Journal
Current drug research reviews
ISSN: 2589-9783
Titre abrégé: Curr Drug Res Rev
Pays: United Arab Emirates
ID NLM: 101735701
Informations de publication
Date de publication:
11 Aug 2023
11 Aug 2023
Historique:
received:
14
04
2023
revised:
06
06
2023
accepted:
16
06
2023
medline:
23
8
2023
pubmed:
23
8
2023
entrez:
23
8
2023
Statut:
aheadofprint
Résumé
Brain-derived neurotrophic factor (BDNF) has been proposed as a treatment for neurodegeneration, including diseases of the cerebellum, where BDNF levels or those of its main receptor, TrkB, are often diminished relative to controls, thereby serving as replacement therapy. Experimental evidence indicates that BDNF signaling countered cerebellar degeneration, sensorimotor deficits, or both, in transgenic ATXN1 mice mutated for ataxin-1, Cacna1a knock-in mice mutated for ataxin-6, mice injected with lentivectors encoding RNA sequences against human FXN into the cerebellar cortex, Kcnj6Wv (Weaver) mutant mice with granule cell degeneration, and rats with olivocerebellar transaction, similar to a BDNF-overexpressing transgenic line interbred with Cacng2stg mutant mice. In this regard, this study discusses whether BDNF is effective in cerebellar pathologies where BDNF levels are normal and whether it is effective in cases with combined cerebellar and basal ganglia damage.
Identifiants
pubmed: 37609676
pii: CDRR-EPUB-133548
doi: 10.2174/2589977515666230811093021
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.